Huaren Pharmaceutical Co., Ltd.

XSEC:300110 Stock Report

Market Cap: CN¥3.7b

Huaren Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Huaren Pharmaceutical has been growing earnings at an average annual rate of 24.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 2.3% per year. Huaren Pharmaceutical's return on equity is 5.4%, and it has net margins of 9.8%.

Key information

24.1%

Earnings growth rate

24.0%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate2.3%
Return on equity5.4%
Net Margin9.8%
Next Earnings Update23 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Huaren Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300110 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,49414715675
30 Jun 241,57917921375
31 Mar 241,64019825072
31 Dec 231,63618826269
30 Sep 231,73119538259
30 Jun 231,72718937859
31 Mar 231,63719732959
01 Jan 231,61918136955
30 Sep 2239113641554
30 Jun 221,58013142754
31 Mar 221,60313145758
01 Jan 221,56113044264
30 Sep 212,57815832566
30 Jun 211,43313334563
31 Mar 211,41911436361
31 Dec 201,3179535855
30 Sep 201,3837144859
30 Jun 201,3376449860
31 Mar 201,3704358957
31 Dec 191,4624263462
30 Sep 191,4683668061
30 Jun 191,4453567760
31 Mar 191,3944164757
31 Dec 181,3843963756
30 Sep 181,4044262253
30 Jun 181,3764555174
31 Mar 181,3643652965
01 Jan 181,3123850449
30 Sep 171,2543347232
30 Jun 171,253294930
31 Mar 171,244264660
31 Dec 161,249244390
30 Sep 161,20964350
30 Jun 161,18753910
31 Mar 161,140103920
31 Dec 151,106233820
30 Sep 151,013293540
30 Jun 151,010453530
31 Mar 15961423350
31 Dec 14917563180
30 Sep 141,004963130
30 Jun 149121053040
31 Mar 149051252860

Quality Earnings: 300110 has high quality earnings.

Growing Profit Margin: 300110's current net profit margins (9.8%) are lower than last year (11.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300110's earnings have grown significantly by 24.1% per year over the past 5 years.

Accelerating Growth: 300110's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300110 had negative earnings growth (-24.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 300110's Return on Equity (5.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 04:46
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Huaren Pharmaceutical Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jun LiuChangjiang Securities Co. LTD.
Jie YaoEverbright Securities Co. Ltd.
Jianjian LiFounder Securities Co., Ltd.